Ergothioneine for Stage IV Cancer
Also known as: ERGO, L-ergothioneine
ERGO may modulate tumor immune responses and protect normal tissue during cancer treatment.
Mechanism of Action
ERGO protects immune cells from oxidative damage during anti-tumor responses, maintains T cell and NK cell viability, and may reduce treatment-induced immunosuppression. It also protects normal tissue from radiation and chemotherapy oxidative damage.
General mechanism: Unique thiol-histidine amino acid. OCTN1-transported, mitochondrial antioxidant, metal chelator, hydroxyl radical scavenger.
Current Evidence
Protective effects on immune cells documented. Cancer-specific studies limited. OCTN1 expression varies by tumor type.
Clinical Status: Preclinical for immune support. Available as supplement.
Safety Profile
Extremely safe. Naturally present in diet (mushrooms). Dedicated OCTN1 transporter suggests biological importance. No side effects.
Key Research Questions
- Can ERGO enhance anti-tumor immune cell persistence?
- Does tumor OCTN1 expression affect ERGO's cancer biology effects?